Involving Immunoglobulin Or Antibody Fragment, (e.g., F(ab)'2, Fab', Fab, Fv, Fc, Heavy Chain, Light Chain, Etc.) Patents (Class 530/866)
-
Patent number: 5608039Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.Type: GrantFiled: October 28, 1994Date of Patent: March 4, 1997Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
-
Patent number: 5605690Abstract: A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.Type: GrantFiled: February 8, 1995Date of Patent: February 25, 1997Assignee: Immunex CorporationInventors: Cindy A. Jacobs, Craig A. Smith
-
Patent number: 5559094Abstract: Analogs of human insulin containing an aspartic acid at position 1 of the B chain (Asp.sup.B1), and optionally, having a gln modification at position 13 (Gln.sup.B13), display modified physico-chemical and pharmacokinetic properties which enable them to be long acting. These analogs are useful in the treatment of hyperglycemia because they are soluble and display an increased tendency to self-associate.Type: GrantFiled: August 2, 1994Date of Patent: September 24, 1996Assignee: Eli Lilly and CompanyInventors: David N. Brems, Diane L. Bakaysa
-
Patent number: 5534255Abstract: This invention provides a monoclonal antibody or its fragment specific to a human .alpha..sub.2 -plasmin inhibitor, said antibody having the function of specifically blocking that site of the human .alpha..sub.2 -plasmin inhibitor which inhibits the fibrinolytic activity of plasmin, and of suppressing said fibrinolytic activity inhibiting function of said .alpha..sub.2 -plasmin inhibitor, and also a hybridoma capable of producing the monoclonal antibody. Said monoclonal antibody or its fragment is useful for the immunological determination of a human .alpha..sub.2 -plasmin inhibitor, the separation or recovery of a human .alpha..sub.2 -plasmin inhibitor from a liquid containing the human .alpha..sub.2 -plasmin inhibitor, and the treatment of a thrombotic disease.Type: GrantFiled: June 17, 1991Date of Patent: July 9, 1996Assignee: Teijin LimitedInventors: Yoshihiko Sumi, Yukiya Koike, Yataro Ichikawa, Nobuhiko Yoshida, Nobuo Aoki
-
Patent number: 5521288Abstract: The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.Type: GrantFiled: March 29, 1994Date of Patent: May 28, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady
-
Patent number: 5500215Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.Type: GrantFiled: November 3, 1994Date of Patent: March 19, 1996Assignee: The Biomembrane InstituteInventor: Sen-itiroh Hakomori
-
Patent number: 5460785Abstract: Proteins containing one or more dtsulfide bonds or monosulfides are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologtc conditions. Labeling is accomplished with a variety of metals, including radiometals, by using a reducing agent to reduce the disulfide bonds to thiolate groups; excess reducing agent, reaction by-products and any impurities are removed; and, a source of Sn (II) agent is added to the thiolate-containing protein. The resulting product may be stored frozen or lyophilized, with labeling accomplished by the addition of the medically useful metal ions.Type: GrantFiled: January 3, 1992Date of Patent: October 24, 1995Assignee: RhoMed IncorporatedInventors: Buck A. Rhodes, Paul O. Zamora
-
Patent number: 5447846Abstract: An enzyme-labelled antibody adapted for use in a homogeneous immunoassay is provided. The enzyme-labelled antibody is a conjugate of an enzyme with two or more different monoclonal antibodies, each of the monoclonal antibodies being capable of specifically recognizing and binding to a different epitope of the same antigen. By using the enzyme-labelled antibody in the homogeneous enzyme immunoassay process, an analyte can be quantitatively analyzed at a higher sensitivity through a simple operation. Also provided is a dry immunoassay element comprising an immunological reaction layer containing the enzyme-labelled antibody. By the provision of such an immunoassay element, a further simplified quick analysis of an analyte is realized to give an accurate result.Type: GrantFiled: July 14, 1993Date of Patent: September 5, 1995Assignee: Fuji Photo Film C., Ltd.Inventors: Hiroshi Shinoki, Masashi Ogawa
-
Patent number: 5434131Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: GrantFiled: May 26, 1993Date of Patent: July 18, 1995Assignee: Bristol Myers Squibb Co.Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady
-
Patent number: 5346687Abstract: Antibody against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be store frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide.Type: GrantFiled: January 3, 1992Date of Patent: September 13, 1994Assignee: Rhomed IncorporatedInventor: Buck A. Rhodes
-
Patent number: 5324510Abstract: The present invention provides a method of reducing the severity of asthma. Specifically, the present invention discloses that anti-adhesion antibodies, such as anti-ICAM-1 or anti-CD18 family member antibodies, when administered to a mammal, are capable of decreasing the hyperresponsive reaction associated with an asthmatic response.Type: GrantFiled: March 18, 1993Date of Patent: June 28, 1994Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Craig D. Wegner, Robert H. Gundel, Robert Rothlein
-
Patent number: 5277589Abstract: For the determination of antibodies based on an immunoassay technique by incubation with at least three receptors R.sub.1, R.sub.2 and R.sub.3 which are present dissolved in a liquid phase and of which R.sub.1 is an antigen which is capable of being specifically bound to the antibody to be determined, R.sub.2 mediates the binding to the solid phase and R.sub.3 carries a label, separation of the complex which forms from the solution by binding to a solid phase and measurement of the label in one of the phases, a conjugate is used as the receptor R.sub.2 composed of a receptor capable of specific binding to R.sub.1 and a substance S.sub.1, which can be specifically bound, and a conjugate of a receptor which can specifically bind to R.sub.1 and a label is used as R.sub.3, wherein the immobilization of the complex which forms is mediated by binding to a component of the solid phase which can specifically bind S.sub.1.Type: GrantFiled: March 1, 1991Date of Patent: January 11, 1994Assignee: Boehringer Mannheim GmbHInventors: Urban Schmitt, Wolfgang Rudinger, Gertraud Ehrlich-Weinreich
-
Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
Patent number: 5245015Abstract: The monoclonal antibodies (mAbs) of the invention bind to a neutralizing epitope on the gp120 glycoprotein of HIV-1. The binding seems to be conformation-dependent, in the sense that altering the conformation of gp120 (by deglycosylating the gp120, by reducing the cysteine bonds in the peptide backbone) will inhibit the binding. The mAbs of the invention are group specific and can neutralize different strains and different isolates of HIV-1. The binding of these mAbs to gp120 is enhanced by the binding of other antibodies to the principal neutralizing determinant (amino acid residue numbers 296-331) of gp120.Type: GrantFiled: April 26, 1991Date of Patent: September 14, 1993Assignee: Tanox Biosystems, Inc.Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun -
Patent number: 5242687Abstract: Specific and nonspecific immunomodulation, enhancement of cellular engraftment, and modulation of nonimmune cells are achieved by using various membrane-binding and soluble CD8 compositions.Type: GrantFiled: April 25, 1991Date of Patent: September 7, 1993Assignee: TKB Associates Limited PartnershipInventors: Mark L. Tykocinski, David R. Kaplan
-
Patent number: 5182368Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.Type: GrantFiled: May 24, 1991Date of Patent: January 26, 1993Inventors: Jeffrey A. Ledbetter, Edward A. Clark
-
Patent number: 5160723Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the coloretal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: March 18, 1991Date of Patent: November 3, 1992Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5120526Abstract: Protein conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the polypeptide compositions efficiently.Type: GrantFiled: February 4, 1991Date of Patent: June 9, 1992Assignee: NeoRx CorporationInventors: Alan R. Fritzberg, Sudhakar Kasina, Ananthachari Srinivasan, Daniel S. Wilbur
-
Patent number: 5116944Abstract: Conjugates comprising a therapeutically effective proteinaceous active moiety linked to an albumin moiety which exhibit enhanced serum half-life and stability properties are disclosed. The conjugates may additionally comprise targeting moieties to facilitate selective localization of the active moiety at a target site. Conjugates of the present invention comprising an albumin moiety additionally exhibit reduced toxicity, yet maintain a high degree of selectivity and potency.Type: GrantFiled: December 29, 1989Date of Patent: May 26, 1992Assignee: NeoRx CorporationInventors: Gowsala P. Sivam, A. Charles Morgan, Jr.
-
Patent number: 5116596Abstract: The invention relates to a process for the preparation of an organ-specific substance labeled with technetium-99m, in which an organ-specific substance, or an organ-specific substance which has been pretreated or coupled to a complexing agent for technetium-99m, is mixed with [99m]-pertechnetate and a complex-stabilized reducing agent.Type: GrantFiled: October 27, 1989Date of Patent: May 26, 1992Assignee: Hoechst AktiengesellschaftInventors: Karl-Heinz Bremer, Ludwig Kuhlmann, Alexander Schwarz, Axel Steinstrasser
-
Patent number: 5116948Abstract: Islet Amyloid Polypeptide substantially free of Islet Amyloid which can be isolated from Islet Amyloid of different mammals and when isolated from humans it has the following amino acid sequence in positions 1-37: ##STR1##Type: GrantFiled: April 30, 1990Date of Patent: May 26, 1992Assignee: Regents of the University of MinnesotaInventors: Per Westermark, Kenneth H. Johnson
-
Patent number: 5106956Abstract: Glycoprotein which inactivates ribosomes (GPIR) having the ribosome-inhibiting activity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.Type: GrantFiled: September 8, 1989Date of Patent: April 21, 1992Assignee: SanofiInventors: Pierre Casellas, Bernard Bourrie, Xavier Canat
-
Patent number: 5099005Abstract: Methods of enhancing immunoglobulin fragment yield of immunoglobulins exhibiting anomalous bands when analyzed by SDS-PAGE techniques are provided. Such yield enhancement methods include the steps of desialylating the immunoglobulin; and fragmenting the immunoglobulin produced in the desialylating step. A particular advantage of the present invention is that the fragmention step can be carried out in the presence of cysteine without decreasing the quality of the immunoglobulin fragment product. Methods of enhancing the molecular weight homogeneity of immunoglobulin or fragmented immunoglobulin exhibiting anomalous bands when analyzed by SDS-PAGE techniques are also discussed. These methods include the steps of desialylating the immunoglobulin or fragmented immunoglobulin and purifying the desialylated product.Type: GrantFiled: September 28, 1990Date of Patent: March 24, 1992Assignee: NeoRx CorporationInventors: Everett J. Nichols, Robert F. McIntyre
-
Patent number: 5096704Abstract: A method of preventing eosinophilia associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-5. Preferably, the antagonist is a blocking monoclonal antibody specific for human interleukin-5, or a fragment or binding composition derived therefrom.Type: GrantFiled: July 23, 1990Date of Patent: March 17, 1992Assignee: Schering CorporationInventors: Robert L. Coffman, Donna M. Rennick